New device aims to filter toxins in liver crisis
NCT ID NCT06079021
First seen May 04, 2026 · Last updated Jun 19, 2026 · Updated 11 times
Summary
This study tests whether adding the CytoSorb blood-filtering device to standard hospital care can better remove waste products like bilirubin and ammonia in people with sudden worsening of chronic liver disease. Twenty adults with severe liver failure will receive the device for 72 hours, and their outcomes will be compared to a similar group from the past who got standard care alone. The goal is to see if the device can reduce liver toxins and improve brain function during this critical illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UZA
RECRUITINGEdegem, Antwerp, 2650, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.